From the Guidelines
Jardiance (empagliflozin) can cause dry skin as a side effect due to its mechanism of action as an SGLT2 inhibitor, which increases glucose excretion through urine and can lead to fluid loss and dehydration. To manage this side effect, several strategies can be employed:
- Staying well-hydrated by drinking plenty of water throughout the day is crucial, as Jardiance increases urination 1.
- Applying a fragrance-free moisturizer regularly, especially after bathing while skin is still damp, can help lock in moisture.
- Considering the use of a humidifier in the home, particularly during dry seasons or if heating or air conditioning is used frequently, may also be beneficial.
- Avoiding hot showers or baths, which can further dry out the skin, and instead using lukewarm water is recommended. If dry skin persists or becomes severe, it is essential to consult a healthcare provider, who may recommend adjusting the medication or prescribe specific treatments 1. It's crucial not to discontinue Jardiance without medical advice, as it provides important benefits for managing diabetes or heart failure, including reducing the risk of major adverse cardiovascular events and hospitalization for heart failure 1. Overall, managing dry skin associated with Jardiance requires a multifaceted approach that includes hydration, skin care, and potentially adjusting treatment plans under the guidance of a healthcare provider.
From the Research
Jardiance and Dry Skin
- There is no direct evidence in the provided studies that links Jardiance (empagliflozin) to dry skin as a side effect 2, 3, 4, 5.
- However, one study mentions that the diuretic action of empagliflozin can lead to volume depletion and a fall in blood pressure, especially during co-administration with other diuretics or antihypertensive drugs 4.
- Another study discusses the prevention, recognition, and treatment of dry skin conditions, but it does not mention empagliflozin or Jardiance specifically 6.
- The studies primarily focus on the efficacy and safety of empagliflozin in patients with type 2 diabetes, its effects on cardiovascular outcomes, and its potential benefits and risks 2, 3, 4, 5.